A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites During the Occurrence and Development of Nasopharyngeal Carcinoma in Southern China.

Nanfang Hospital, Southern Medical University1 site in 1 country2,000 target enrollmentDecember 23, 2022

ConditionsNasopharyngeal Carcinoma EBV Infection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Nasopharyngeal Carcinoma
Sponsor: Nanfang Hospital, Southern Medical University
Enrollment: 2000
Locations: 1
Primary Endpoint: Achieve the expected number of enrolled cases
Status: Recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. Therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.

Registry

clinicaltrials.gov

Start Date

December 23, 2022

End Date

December 20, 2025

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Nanfang Hospital, Southern Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with previous infection;
•Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard);
•Healthy people: Healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the Physical Examination Center of Southern Hospital.

Exclusion Criteria

•People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes);
•Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
•Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease;
•Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose\>1.5 × Upper limit of normal value), mental illness and severe allergic history.
•BMI is less than 18 or more than